Dmitriy Niyazov1,2, Diego A Lara1,2. 1. Department of Pediatrics, Ochsner Hospital for Children, Ochsner Clinic Foundation, New Orleans, LA. 2. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.
Abstract
BACKGROUND: Pompe disease is a lysosomal storage disorder that results from an inborn error of metabolism involving abnormal glycogen storage. Infantile-onset Pompe disease is the most severe phenotype, and enzyme replacement therapy with alglucosidase alfa (Lumizyme) improves medical and functional outcomes in patients with infantile-onset Pompe disease. CASE REPORT: We report the case of a patient with infantile-onset Pompe disease who presented with severe hypertrophic cardiomyopathy, systolic and diastolic cardiac dysfunction, and hypotonia. She experienced significant improvement in cardiac systolic function while receiving enzyme replacement therapy. CONCLUSION: Typically, patients with infantile-onset Pompe disease and severe hypertrophic cardiomyopathy are not as responsive to enzyme replacement therapy as patients with mild or no hypertrophic cardiomyopathy. We demonstrated the efficacy of enzyme replacement therapy in a patient with severe hypertrophic cardiomyopathy.
BACKGROUND: Pompe disease is a lysosomal storage disorder that results from an inborn error of metabolism involving abnormal glycogen storage. Infantile-onset Pompe disease is the most severe phenotype, and enzyme replacement therapy with alglucosidase alfa (Lumizyme) improves medical and functional outcomes in patients with infantile-onset Pompe disease. CASE REPORT: We report the case of a patient with infantile-onset Pompe disease who presented with severe hypertrophic cardiomyopathy, systolic and diastolic cardiac dysfunction, and hypotonia. She experienced significant improvement in cardiac systolic function while receiving enzyme replacement therapy. CONCLUSION: Typically, patients with infantile-onset Pompe disease and severe hypertrophic cardiomyopathy are not as responsive to enzyme replacement therapy as patients with mild or no hypertrophic cardiomyopathy. We demonstrated the efficacy of enzyme replacement therapy in a patient with severe hypertrophic cardiomyopathy.
Entities:
Keywords:
Cardiomyopathy–hypertrophic; enzyme replacement therapy; glycogen storage disease type II
Authors: Laura E Case; Carl Bjartmar; Claire Morgan; Robin Casey; Joel Charrow; John P Clancy; Majed Dasouki; Stephanie DeArmey; Khan Nedd; Mary Nevins; Heidi Peters; Dawn Phillips; Zachary Spigelman; Cynthia Tifft; Priya S Kishnani Journal: Neuromuscul Disord Date: 2014-12-19 Impact factor: 4.296
Authors: A Broomfield; J Fletcher; J Davison; N Finnegan; M Fenton; A Chikermane; C Beesley; K Harvey; E Cullen; C Stewart; S Santra; S Vijay; M Champion; L Abulhoul; S Grunewald; A Chakrapani; M A Cleary; S A Jones; A Vellodi Journal: J Inherit Metab Dis Date: 2015-10-26 Impact factor: 4.982
Authors: J Hordeaux; L Dubreil; C Robveille; J Deniaud; Q Pascal; B Dequéant; J Pailloux; L Lagalice; M Ledevin; C Babarit; P Costiou; F Jamme; M Fusellier; Y Mallem; C Ciron; C Huchet; C Caillaud; M-A Colle Journal: Acta Neuropathol Commun Date: 2017-09-06 Impact factor: 7.801
Authors: C M van Gelder; E Poelman; I Plug; M Hoogeveen-Westerveld; N A M E van der Beek; A J J Reuser; A T van der Ploeg Journal: J Inherit Metab Dis Date: 2016-01-14 Impact factor: 4.982